Athira Pharma Presents Preclinical Data at the 2022 Peripheral Nerve Society (PNS) Annual Meeting
May 16 2022 - 7:00AM
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage
biopharmaceutical company focused on developing small molecules to
restore neuronal health and slow neurodegeneration, today announced
the presentation of preclinical data on two small molecule positive
modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019,
at the 2022 Peripheral Nerve Society (PNS) Annual Meeting.
The research highlights the effect of ATH-1018 and ATH-1019 on
neuropathic pain-related behaviors in a preclinical model of
streptozotocin (STZ)-induced diabetic neuropathy. Data demonstrate
that measures of pain-related behaviors were significantly improved
on testing days across all dose levels for each molecule.
Pain-related behaviors were also significantly reduced prior to
dosing on day 25 when ATH-1018 or ATH-1019 had been cleared from
plasma, suggestive of potentially persistent pain-modifying
effects.
“Previous work has identified the HGF/MET pathway as a potential
therapeutic target for peripheral neuropathies, including diabetic
neuropathy, which features components of nerve damage and
inflammation. Our preclinical data demonstrates the potential of
ATH-1018 and ATH-1019 as therapeutic candidates for painful
diabetic neuropathy,” said Kevin Church, Ph.D., Executive Vice
President, Research of Athira. “We look forward to the continued
evaluation of these candidates to further support our pipeline
expansion.”
The poster “Small Molecule HGF/MET Positive Modulator
Effectively Reduces Pain-Related Behaviors in a Rat Diabetic
Neuropathy Model” can be found on the Scientific Publications &
Presentations page of the company’s website at www.athira.com.
The poster is also viewable on the PNS conference website to
registrants through Dec. 31, 2022.
About Athira Pharma, Inc. Athira Pharma Inc.,
headquartered in the Seattle area, is a late clinical-stage
biopharmaceutical company focused on developing small molecules to
restore neuronal health and slow neurodegeneration. Athira aims to
provide rapid cognitive improvement and alter the course of
neurological diseases with its novel mechanism of action. Athira is
currently advancing its pipeline therapeutic candidates, targeting
the HGF/MET neurotrophic system, for Alzheimer’s and Parkinson’s
disease dementia, Dementia with Lewy bodies and neuropsychiatric
indications. For more information, visit www.athira.com. You can
also follow Athira on Facebook, LinkedIn and @athirapharma on
Twitter and Instagram.
Forward-Looking Statements This release
contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding Athira’s product
candidates, including ATH-1018 and ATH-1019 as therapeutic
candidates for peripheral diabetic neuropathy; Athira’s platform
technology and potential therapies; future development plans;
clinical and regulatory objectives and the timing thereof;
expectations regarding the potential efficacy and commercial
potential of Athira’s product candidates; the anticipated reporting
of data; and Athira’s ability to advance its product candidates
into later stages of development. Forward-looking statements
generally include statements that are predictive in nature and
depend upon or refer to future events or conditions, and include
words such as “may,” “will,” “should,” “on track,” “would,”
“expect,” “plan,” “believe,” “intend,” “pursue,” “continue,” and
other similar expressions, among others. Any forward-looking
statements are based on management’s current expectations of future
events and are subject to a number of risks and uncertainties that
could cause actual results to differ materially and adversely from
those set forth in or implied by such forward-looking statements.
These risks and uncertainties include, but are not limited to, the
preliminary data for Athira’s product candidates will not continue
or persist in current or planned clinical trials; cessation or
delay of any of the ongoing clinical trials and/or Athira’s
development of ATH-1018, ATH-1019 and other product candidates may
occur; future potential regulatory milestones of ATH-1018 and
ATH-1019 and other product candidates, including those related to
current and planned clinical studies, may be insufficient to
support regulatory submissions or approval; the impact of the
COVID-19 pandemic on Athira’s business, research and clinical
development plans and timelines, and results of operations,
including impact on Athira’s clinical trial sites and contractors
who act for or on Athira’s behalf, may be more severe and more
prolonged than currently anticipated; the regulatory process for
Athira product candidates; the outcome of legal proceedings which
have been or may in the future be instituted against us and certain
of our directors and officers; clinical trials may not demonstrate
safety and efficacy of any of Athira’s product candidates; Athira’s
research and development efforts and its ability to advance product
candidates into later stages of development may fail; any one or
more of Athira’s product candidates may not be successfully
developed, approved or commercialized; adverse conditions in the
general domestic and global economic markets; the impact of
competition; regulatory agencies may be delayed in reviewing,
commenting on or approving any of Athira’s clinical development
plans as a result of the COVID-19 pandemic, which could further
delay development timelines; the impact of expanded product
development and clinical activities on operating expenses; the
impact of new or changing laws and regulations; Athira’s
assumptions regarding the sufficiency of its cash, cash equivalents
and investments to fund its planned operations may be incorrect; as
well as the other risks detailed in Athira’s filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof and Athira undertakes
no obligation to update forward-looking statements. Athira may not
actually achieve the plans, intentions, or expectations disclosed
in its forward-looking statements, and you should not place undue
reliance on the forward-looking statements.
Investor & Media Contact:
Julie Rathbun Athira Pharma Julie.rathbun@athira.com
206-769-9219
Athira Pharma (NASDAQ:ATHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athira Pharma (NASDAQ:ATHA)
Historical Stock Chart
From Apr 2023 to Apr 2024